Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSX | NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM), announced today its financial and operational results for the first quarter ended September 30, 2018.
|
EDMONTON, PRNewswire/ - Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSX | NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM), announced today its financial and operational results for the first quarter ended September 30, 2018. Q1 2019 Financial and Operational Highlights
Commencement of Sales to Canadian Adult Consumer Use Market Provincial Highlights (for the period up to October 31, 2018):
Q1 2019 Highlights:
Management Commentary “We continue to successfully execute our differentiated and diversified strategy committed towards domestic and international expansion in the medical cannabis market, adult consumer use sales, production scale-up, innovation, plant and medical research, and product development,” said Terry Booth, CEO of Aurora. “The commencement of adult consumer use sales in Canada has been very successful for Aurora, with strong performance across all product categories and brands. Our initial roll-out success demonstrates how our high-quality Aurora Standard products and well-positioned brands have resonated strongly with the consumer market and our preparedness for the logistical challenges in effectively bringing our products to market. Given the strong unmet consumer demand evident across Canada, we are confident that our rapidly increasing production capacity will result in continued acceleration of revenue growth.” Mr. Booth added, “We also continue to perform well in our international medical business. With the acquisition of ICC Labs, which we expect to close in the coming weeks, we are establishing leadership in Latin America. In addition to ongoing international growth and expansion led by our team at Aurora Europe, we were also the first non-government organization to export medical cannabis to Poland, a medical market with a population roughly equal to Canada. Across our international activities, we have established significant early mover advantage and market leadership. With the scale-up of our domestic and international production facilities, we anticipate increased availability of product to service these developing markets which will drive further global growth for the Company.” Glen Ibbott, CFO, added, “In Q1 2019, we continued to propel Aurora’s growth making critical investments in our corporate, sales, and marketing talent and capabilities. A significant portion of our Q1 2019 marketing spend was in preparation for the adult consumer use market with numerous branding and market awareness initiatives. With more restrictive marketing regulations in effect as of October 17th, we will see a significant reduction in average marketing spend over the remainder of the fiscal year. We also anticipate a reduction in other one-off expenditures, such as the integration costs related to the MedReleaf, CanniMed, and Anandia acquisitions.” Mr. Booth concluded, “As a science, medical and patient focused organization, we are committed to continue serving our patients with the products they require. As we built up inventory levels in anticipation of the adult consumer use market, we prioritized product availability for our over 67,000 existing patients. With production ramping up, we anticipate once again pro-actively driving additional growth in this core medical segment, both domestically and internationally.” Q1 2019 and Subsequent Operational Highlights Facilities and Production update During and subsequent to the quarter, the Company made significant progress towards increasing its production capacity, including receipt of various sales and production licenses. Based on grow rooms in production, the Company currently is running at an annualized run rate of 70,000 kg. Management anticipates that around calendar year end 2018 into the beginning of calendar 2019, Aurora will have a production run rate in excess of 150,000 kg per annum based on grow rooms in production, with subsequent scale up to over 500,000 kg per annum (excluding additional capacity through the acquisition of ICC Labs). Aurora Sky On October 17, 2018, the Company received its Health Canada sales license for Aurora Sky, allowing Aurora to increase product availability across Canada. Facility construction is now materially complete, including exterior structure, landscaping, commissioning, and harvest and waste rooms. Aurora continues to populate additional bays at the facility, with all 17 rooms anticipated to be ready to receive plants within the coming month, and the facility fully planted around calendar year end, ramping up to full capacity. The recently planted rooms were populated using the successfully commissioned automation systems, which function as anticipated, resulting in substantially increased facility efficiencies as compared to traditional greenhouses or indoor grow facilities. Aurora Sky is a technologically highly sophisticated facility, built to deliver exceptional operational efficiencies, including energy, water and nutrient use. In addition to harnessing the power of the sun through the use of highly specialized glass with strong light diffusing characteristics, the Company captures the excess heat generated in the facility during the day, storing it in the successfully commissioned heat sink to be reused when additional heat energy is required, usually during night time hours. The facility is also set up to harness the higher ambient temperatures during the warmer months to supply additional free heat, while the colder months provide free additional cooling capacity. The electricity consumed by the facility is supplied through two independent sub-stations, which feed two independent electrical rings. The rings have interconnects, as well as a back-up independent power generator, to ensure full redundancy. Furthermore, the electrical rings are monitored and controlled by a digitalized management system with switch gear to move power through the facility quickly and efficiently. The measures described above ensure a very significant reduction in energy use compared to more traditional facilities that yield a similar production output on an annual basis. Aurora Mountain On July 30, 2018, the Company received a Health Canada dealer’s license for its Mountain Facility in Cremona, Alberta. This license allows Aurora to expand research and product development activities with cannabinoids and their derivatives not covered under the Cannabis Act, as well as import and export cannabis products to and from international markets, subject to applicable regulations. On September 28, 2018, Aurora Mountain also received its Health Canada production license to produce encapsulated oils. Aurora is producing unique, integral hard-shell capsules for the medical and adult consumer use markets. Aurora Vie The Company received its sales license for Aurora Vie in July 2018. The facility is now operating at full capacity, producing at a run rate of 4,000 kg per annum. On August 22, 2018, the Company received Health Canada authorization to begin production of cannabis softgel capsules at its Aurora Vie facility in Pointe-Claire, Quebec. On October 17, 2018, the Company received its Health Canada softgel sales license. The Company utilizes technology it has exclusively licensed from strategic partner Capcium, in which Aurora has a strategic investment. High volume production of softgels at Vie has started, resulting in greater availability of this higher margin product. Aurora Eau On September 7, 2018, Aurora received a Health Canada production license for its Eau facility in Lachute, Quebec. Aurora Eau was purpose-built to EU GMP standards and represents the next evolution of Aurora’s indoor-grow facilities, where novel and exotic strains will be grown for both the medical and adult consumer-use markets. Aurora Eau, which is fully planted with first harvest anticipated shortly, was officially opened on November 5, 2018. Aurora Nordic, Phase I and II On August 13, 2018, the Company successfully shipped cultivars from Aurora Mountain to Odense, Denmark to commence populating the Aurora Nordic Phase I facility, named “Base One”. The facility is ramping up to its full 8,000 kg per annum capacity, increasing product availability for the EU markets. The Company has commenced with a 54,000 square feet expansion of Base One, anticipated to be fully completed towards the end of the first calendar quarter of 2019. Pharma-grade processing equipment will be moved into the facility, with completion and full commission anticipated for early 2019. Construction of Aurora Nordic Phase II, named “Nordic Sky”, has commenced with site preparation, ground and drainage work. MedReleaf Markham On August 13, 2018, Aurora, through its wholly-owned subsidiary MedReleaf, received EU GMP certification on its facility in Markham, Ontario. This certification will allow MedReleaf Markham to access rapidly growing, higher margin, heavily regulated EU markets. MedReleaf Bradford On September 7, 2018, the Company, through its wholly-owned subsidiary MedReleaf, received its Health Canada oils production license for its facility located in Bradford, Ontario. This license allows MedReleaf Bradford, a 210,000 square foot facility which features a high-volume CO2 extraction facility, to significantly increase the production of oils in fiscal 2019. MedReleaf Bradford continues to produce oils, a higher-margin product, in anticipation of the receipt of its oils sales license. To date, Bradford has completed 13 cultivation rooms, 5 drying rooms, 2 trim rooms, an extraction room, packaging area and the vault. Two additional grow rooms were recently commissioned with only two grow rooms remaining to be licensed. Aurora Sun On April 16, 2018, the Company acquired approximately 71 acres of land in Medicine Hat, Alberta, for the construction of “Aurora Sun”, a 1.2 million square foot, highly automated cannabis production facility with ultra-low operating costs. Construction of Aurora Sun is on schedule with site preparation, backfilling, and 80% of pilings completed to date. Aurora expects to commence erecting the buildings metal frame in the beginning of calendar year 2019. Near completion of the piling work is a major milestone as it ensures greater efficiency of construction work during the winter months. CanniMed On July 3, 2018, the Company, through its wholly-owned subsidiary, CanniMed, received Health Canada authorization to commence sales of CanniMed capsules, a line of vegan capsules which became available to patients on August 22, 2018. Facility upgrades are continuing, and increased yields and efficiencies are already being realized. Innovation The Company is successfully executing on a comprehensive innovation strategy that covers the entire cannabis industry value chain from breeding and genetics, through facility development to medical research product development and post production analytics. Objective of the innovation strategy is to yield industry leading operational efficiencies, as well as the development of a broad portfolio of high-margin, targeted medical and consumer use products. Medical Research
Product Development
Acquisitions Aurora has been executing successfully on developing a fully vertically integrated company. This strategy combines both organic initiatives and M&A. To date the Company has completed over 25 transactions (acquisitions and strategic investments), covering the entire spectrum of the cannabis industry value chain. Consequently, Aurora has been successful in establishing leadership across its activities and is exceptionally well positioned to capitalize on its early mover advantage globally, across its medical, wellness, and adult consumer use market segments.
Strategic Investments
To date, ACI’s management, board, and advisory teams have completed the following strategic investments and financing activities:
The Wagner Dimas technology has now been installed at Aurora, and the large-scale production of pre-rolled product has commenced in order to fulfill orders received from provincial buyers who have begun supplying the Canadian adult-use market.
International Expansion
Financing and Capital Market Activities
The Company has the option to upsize the facility to $250 million, subject to certain conditions. The debt facility is primarily secured by Aurora’s production facilities and can be repaid without penalty at Aurora’s discretion.
Financial Review Q1 2019 The Company primarily operates in the cannabis market which includes auxiliary support functions such as CanvasRX patient counselling services; ALPS design, engineering and construction services; and cannabis analytical product testing services through the Company’s recent acquisition, Anandia Laboratories Inc. (“Anandia”). With the Cannabis Act effected as of October 17, 2018, Aurora made its first shipments to provinces across Canada at the end of September 2018.
In the first quarter of 2019 (“Q1 2019") total medical cannabis revenue grew to $24.0 million, a 62% increase compared to the fourth quarter of 2018 (“Q4 2018") and a 229% increase compared to the first quarter of 2018 (“Q1 2018"). With the Cannabis Act in effect as of October 17, 2018, the Company completed its first shipments to Canadian provincial wholesalers of the adult-use market just prior to the end of the current quarter and recorded $0.6 million in adult-use cannabis sales. Total revenue grew to $29.7 million in Q1 2019, representing a 55% increase compared to Q4 2018 and a 260% increase compared to Q1 2018. Revenue growth compared to the same quarter in the prior year was attributable mainly to higher patient numbers following the acquisition of CanniMed and MedReleaf, increased product availability through scale up of operations from the CanniMed and MedReleaf acquisitions, an increase in the average net selling price of dried cannabis, development of international markets, the commencement of the Canadian adult-use market, and product diversification. The average net selling price of cannabis sold was $9.19 per gram in Q1 2019, consistent with Q4 2018, and a 12% increase compared to Q1 2018 as a result of an increase in cannabis extracts sold. Total product sold was 2,676 kilograms of dried cannabis and cannabis extracts in Q1 2019, an increase of 65% as compared to Q4 2018, and 201% compared to Q1 2018. Total cannabis inventory and biological assets increased 97% to $80.8 million in Q1 2019 compared to Q4 2018 as Aurora chose to constrain international sales in order to continue servicing the Canadian medical market, while building inventory in preparation for the Canadian adult consumer-use market. The increase reflects the addition of MedReleaf’s inventory and biological assets and Aurora’s efforts to bolster its inventory levels to serve the medical markets and prepare for the high demand of the Canadian adult consumer-use market. Cost of sales Cash cost of sales per gram of dried cannabis sold increased by $0.03 to $1.90 in Q1 2019 as compared to the prior quarter (Q4 2018), mainly due to higher packaging costs from the inclusion of MedReleaf’s results and increased overall packaging costs of the Company resulting from stringent regulatory requirements of the Cannabis Act. Cash cost to produce per gram of dried cannabis sold decreased by $0.25, or 15%, to $1.45 in Q1 2019 as compared to Q4 2018, and by 22% as compared to Q1 2018, mostly due to integration of Aurora’s yield expertise at CanniMed facilities. Production costs per gram are expected to decrease significantly once Aurora Sky is fully operational and the efficiencies from automation, scale and yield expertise are realized at all Aurora facilities. Gross Profit Q1 2019 gross profit was $8.1 million, compared to a $20.6 million in Q4 2018. The change in gross profit during the period was partially attributable to higher sales of inventory and lower fair value gains on changes in biological assets, which were partially offset by higher gross profits before fair value adjustments. Operating Expenses Aurora continues to make significant investments in its infrastructure and skilled talent, scaling the organization to better realize the tremendous opportunities ahead in the global medical cannabis markets and the Canadian adult consumer-use market. As a result, general and administration costs (“G&A”) increased to $35.9 million in Q1 2019, compared to $22.6 million in Q4 2018. Sales and marketing costs (S&M) in Q1 2019 increased to $29.4 million dollars, from $14.8 million in Q4 2018, mainly as a result of certain one-time activities and programs specifically for the period leading up to the October 17, 2018 Cannabis Act effective date in Canada. The integration of CanniMed accounted for 17% of the increase to G&A and 12% of the increase to S&M. Net Income Q1 2019 net income increased to $104.2 million, compared to a net income of $79.3 million in Q4 2018 and $3.6 million in Q1 2018. The increase was primarily attributable to the unrealized non-cash gain on derivatives and marketable securities, which was partially offset by increased finance costs, share-based payments, acquisition and project evaluation costs. Cash Position, Cash Flows, and Working Capital Net cash and cash equivalents on hand increased from $89.2 million at the end of Q4 2018 to $147.8 million as at Q1 2019. Working capital at the end of Q1 2019 was $548.4 million, as compared to $144.5 million at the end of Q4 2018. The change in working capital was largely attributable to an adjustment to the Company’s investment in The Green Organic Dutchman (“TGOD”), which was previously treated as an investment in associate and was reported at cost; the investment is now treated as a marketable security and reported at fair value. The inclusion of MedReleaf’s balances accounted for $57.6 million in additional working capital. The Company also has strategic investments in a number of publicly-traded companies. Based on the closing prices at November 9, 2018, the value of the common shares and “in-the-money” warrants held by the Company was $407.57 million. The Company anticipates that it has sufficient liquidity and capital resources to meet all of its currently planned expenditures for at least the next twelve months. Pro-Forma Reconciliation For the three months ended June 30, 2018, pro-forma revenue, including the results of MedReleaf, Anandia Labs, and Agropro/Borela, would have been $35.8 million. Outlook Aurora is exceptionally well‑positioned in all of its active markets, including adult consumer-use market, Canadian medical and the international medical markets, with compelling brands, a broad and expanding product portfolio, and strong patient and consumer recognition. In fiscal 2019, the Company will continue to focus on expanding capacity and sales growth in all its markets, in addition to exploiting further product development and innovation, medical research, continued international expansion and realization of acquisition synergies. Aurora is rapidly accelerating production out of its newly licensed facilities, starting with Aurora Sky, which is expected to ramp to full 100,000 kg per annum capacity over the coming months. The Company anticipates reaching a production run rate of approximately 150,000 kg per annum early in calendar 2019, scaling up subsequently to over 500,000 kg per annum (excluding additional capacity through the pending ICC Labs acquisition) through further “Sky Class” facilities, Aurora Sun and Aurora Nordic. The high degree of automation, and customized and fully controlled growing conditions at the Sky Class facilities are anticipated to result in production costs well below one dollar per gram. Management believes these factors together will deliver high growth and continuously improving margins. While the historic milestone of Canada becoming the first G7 nation to legalize the adult consumer-use market creates a very significant growth opportunity, the Company maintains its position that long term the international medical market has the most significant growth prospects, and is expected to grow to 10 million kilograms per annum according to industry observers. The Company has established significant early mover advantage, has a presence on five continents, and is currently Europe’s largest distributor of medical cannabis. Aurora also currently owns two of the seven cannabis production facilities in the world that are EU GMP certified, and additionally owns one EU GMP certified distribution facility in Germany, ensuring continued access to restrictive markets. Management believes this early mover advantage, coupled with the strength of its growing international management teams, will enable the Company to continue expanding its significant market share in the global medical market. Option Grant Conference Call
About Aurora Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 19 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution. Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification. In addition to Aurora’s rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and the pending acquisition of ICC – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ). Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index. For more information about Aurora, please visit our investor website, investor.auroramj.com Terry Booth, CEO Forward looking statements This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur and include, but are not limited to the variety of cannabis products that Aurora will supply to the adult use market.. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither TSX nor NYSE, nor their Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange and the New York Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company Codes: NYSE:ACB, Toronto:ACB | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View original content:
